Skip to content

Database / Eloralintide

In Phase 3Amylin receptor agonistInjection · Weekly

Eloralintide

No brand yet · Eli Lilly. Lilly's stand-alone amylin drug. At 20% weight loss in Phase 2, it rivals GLP-1 drugs on its own. Also being combined with tirzepatide.

Average weight loss
20.1%
Stopped for side effects
n/r
Trial length
48 wk
Ranking score
n/r

Phase 2 results

Phase 2 · 48 weeks · 9 mg weekly
Adults with obesity or overweight, no diabetes

Weight loss
20.1%
Nausea
n/r
Vomiting
n/r
Diarrhea
n/r
Constipation
n/r
Quit due to side effects
n/r

n/r = not reported. Counting everyone who started, weight loss was 17.5%. Placebo group: 0.4%.

Worth knowing

  • People who started at a low dose and stepped up had stomach side effects similar to placebo.

Next catalysts

End 2026 Phase 3 of eloralintide + tirzepatide combination starts (Company guidance)

–
Not yet ranked
Needs Phase 3 data. We rank only drugs with a completed Phase 3 trial and published side-effect rates.

At a glance

Company
Eli Lilly
Targets
Amylin
Molecule
Peptide
Dosing
Injection, weekly
Status
In Phase 3

Compare with another drug

Sources